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Several biological and clinical considerations
suggest the involvement of cyclooxygenase-2
(COX-2), the key enzyme of prostaglandin (PG)
synthesis, in the pathogenesis and progression of
haematological malignancies. Despite the wealth of
data concerning COX-2 expression, only limited in-
formation is available on multiple myeloma (MM).
Using standard immunohistochemistry we there-
fore evaluated COX-2 protein expression in samples
from 57 patients with a primary diagnosis of MM.
Time to progression and a variety of clinicopatho-
logical features were evaluated by the Kaplan-Meier
method and the Cox regression model. In addition,
COX-2 expression was evaluated by staining bone
marrow from healthy donors and 11 patients with
MGUS. Overall, 31 MM samples (54%)  expressed
COX-2. Positivity for COX-2 was unrelated to stage
or clinical or molecular features of the disease. 
However, patients with COX-2 positive tumours
experienced a significantly shorter time to pro-
gression (17 vs 30 months, p = 0.037). In summary,
COX-2 is frequently expressed in MM and corre-
lates with shorter progression-free survival.
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Multiple myeloma (MM) is a B-cell malig-
nancy characterised by clonal expansion of plasma
cells. It accounts for some 12% of all malignant
haematological neoplasms, and despite the avail-
ability of novel treatment modalities it is still an in-
curable disease with variable median survival of a
few years. Many attempts have been made in the
past to identify routinely applicable prognostic 
and predictive factors in this disease. Recently
COX-2, which is involved in a variety of inflam-
matory processes and syntheses of prostaglandins,
has become a focus of attention in the pathogene-
sis and prognosis of MM. The COX-2 gene, an im-
mediate-early response gene, is rapidly induced by
mitogenic or inflammatory stimuli including tu-
mour promoters, cytokines, growth factors and
others. Among these, cytokines such as IL-6 are
produced by cells of the bone marrow (BM) mi-
croenvironment. These cytokines have been im-
plicated in plasma cell survival and growth, drug
resistance and migration of MM cells, as well as
myeloma-related phenomena such as the develop-
ment of bone destruction and anaemia [1]. COX-
2 expression as a key mediator of prostaglandins
has become a prognostic factor associated with a
poor clinical outcome in many solid cancers.
To date  its role in haematologic malignancies  has
not been well established. We were recently the
first to demonstrate expression of COX-2 in a 
heterogeneous collection of MM samples from pa-
tients at different stages also treated for refractory
and recurrent disease. In this study, labour inten-
sive PCR methodology for RNA transcription and
Western blotting (WB) showed COX-2 expression
to be an independent prognostic factor for both
progression-free and overall survival [2]. The aim
of the current study was therefore twofold: 1) to
evaluate whether COX-2 expression assessed
solely by routinely applicable immunohistochem-
istry (IHC) offers an alternative to the molecular
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methods described for clinical prognosis in MM,
and 2) investigate COX-2 expression in an inde-
pendent and largely homogeneous group of previ-
ously untreated patients from three different insti-
tutions with monoclonal gammopathy of undeter-
mined significance (MGUS) and MM.
Standard IHC was performed on a total of 70 speci-
mens (59 MM, 11 MGUS) and the corresponding COX-
2 expression was analysed for clinical significance. 12 of
the 70 specimens had already been evaluated in our previ-
ous study [2]. Samples were obtained either by bone mar-
row puncture of the posterior iliac crest or surgical resec-
tion/biopsy of an extra-medullary lesion for diagnostic
procedures. Varying fixation and decalcification proce-
dures were used in the individual institutions before paraf-
fin embedding of the bone-containing samples. Clinical
records and follow-up information were available for all
patients, as well as demographic data, M gradient and as-
signed stage according to Durie and Salmon 1975, infor-
mation being obtained after informed consent and coded
for anonymous analysis. b2-microglobulin at diagnosis
was available in 38 patients and chromosome 13 deletion
assessed by fluorescence in situ hybridisation (FISH) in 14
patients. None of the patients had received chemo-,  radio-
or immunotherapy before diagnosis. Time to progression
was calculated from the time of diagnosis to evidence of
progressive disease as defined by the criteria proposed by
Blade et al. Patients’ clinical characteristics at diagnosis are
shown in table 1. To determine COX-2 expression in MM
patients at diagnosis, biopsies were stained using the
COX-2 murine polyclonal affinity-purified antibody (Ab)
(CaymanChemical, Ann Arbor, USA). Immunohisto-
chemistry (IHC) was performed according to the manu-
facturers’ recommendations. Briefly, after deparaffinisa-
tion antigen retrieval was performed by pretreatment with
cell conditioning solution CC1-Buffer pH 6.0 (Ventana
Medical Systems, Tucson, Arizona). Tissue sections were
then incubated with the primary COX-2 Ab for 32 min-
utes (dilution 1:60). Immunoreactivity was visualised
using NIEW DAB detection kit (Ventana Medical Sys-
tems) developing solutions, containing biotinilated strep-
tavidin horse radish peroxidase and 3`3-diamonobenzi-
dine tetrahydrochloride and Hämalaun for counterstain-
ing. A negative control was performed without primary
antibody. HE sections of all biopsies were reviewed in-
dependently by the local haematopathologist of the par-
ticipating institutions. As positive control for the stain-
ability of the different biopsies, which were subjected to
various decalcification procedures, an established cyto-
plasmic plasma cell marker (VS38c, monoclonal, DAKO,
Glostrup, Denmark) was applied. COX-2 staining was fi-
nally assessed by two different investigators who had no
prior knowledge of the clinical parameters (MT and BJ).
The proportion of immunostained plasma cells was calcu-
lated by evaluating the entire bone marrow trephine or
biopsy. When more than 10% of the malignant plasma
cells stained moderately to strongly positive for COX-2,
the case was scored as positive. Staining intensity was eval-
uated using a range from 0 (none), 1 (faint), 2 (moderate)
to 3 (strong). For comparison, we included four tissue
samples containing reactive plasma cells due to inflamma-
tion or autoimmune disease, three normal as well as 11
bone marrow trephines from patients diagnosed with
MGUS. COX-2 expression was correlated in patients at
diagnosis with widely employed prognostic parameters
such as age, sex, BM plasmocytosis, Salmon and Durie
clinical stage (stage I–III), creatinine (<2 or >2 mg/dL) Hb
level (<8 g/dl or >8 g/dl), presence of bone lesions, b2-mi-
croglobulin (>2.4 or <2.4 µg/L), and chromosome 13 dele-
tion assessed by FISH. The Mann-Whitney test and
Fisher’s exact test were used to compare COX-2 positive
and negative cases. A difference between the two groups
was considered to be significant for p <0.05. Progression-
free survival (PFS) was calculated from the date of diag-
nosis to the date of progression and was analysed using the
Kaplan-Meier method. The log-rank test and Cox regres-
sion were applied to analyse the role of clinicopathologi-
cal parameters and COX-2 staining as predictors for time
to progression (TTP). A multivariate Cox regression
(backward stepwise likelihood ratio) was used to deter-
mine independent predictors. All statistical analyses were
performed using SPSS 11.0 (SPSS Inc. Chicago IL).
Methods
COX-2  in reactive tonsils was found to be ex-
pressed strongly and exclusively in plasma cells,
but not in other B-cell or T-cell areas. Plasma cells
infiltrating inflamed tissue also stained strongly
positive for COX-2 (figure 1 A, B). In contrast,
only scattered COX-2-positive cells were detected
in normal bone marrow trephines. In patients with
MGUS we observed no (5 cases) to faint (6 cases)
COX-2 expression in plasma cells, but never such
strong expression as that observed in reactive tis-
sues or in MM. Due to reduced quality of trephines
only 57 of the initial 59 MM samples were finally
evaluable for COX-2 expression. Overall, im-
munoreactivity for COX-2 protein in MM was
scored positive in 31 out of 57 tumours (54%), of
which four (7%) were from extramedullary tu-
mour manifestations (one skin, one nasopharyn-
geal and two soft tissue, all of which exhibited
strong homogeneous immunostaining). In the de-
calcified bone marrow trephines staining inten-
sity varied from faint to strong. The VS38c was
strongly positive in all bone-containing biopsies,
except in two which were excluded from the study.
In contrast, MM from extramedullary localisations
presenting large tumour areas all exhibited mod-
erate to strong VS38c expression in most of the tu-
mour cells. The staining pattern of COX-2 in MM
is shown in figure 1C–F. Correlations were sought
between COX-2 expression at diagnosis and clin-
icopathological parameters. The results of the sta-
tistical analysis for a correlation between COX-2
expression and clinical parameters are shown in
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table 2. COX-2 positivity was not distributed 
differently in relation to age, gender, stage, creati-
nine, Hb level and presence of bone lesions. Nei-
ther could we find a correlation between COX-2
expression on tumour and elevated (>2.4 mg/l) b2-
microglobulin values, and no difference occurred
with respect to deletion of chromosome 13q (as-
sessed by FISH), although our analysis may be lim-
ited due to the number of genetic analyses avail-
able with and without deletion of chromosome 13q
respectively. An outcome analysis based on PFS
was performed in patients assessed at diagnosis.
The median follow up period was 30 months
(range 2–60 months). During the follow-up period
disease progression was observed in 39 patients
(67%). The results obtained from the analysis of
clinicopathological parameters predicting pro-
gression-free survival are shown in table 3. Accord-
ing to univariate analysis neither age, sex, stage nor
b2-microglobulin showed statistical significance.
No %
Total 57 100
Age median (range) 60 (35–86)
Sex (M/F) 37/20 65/35
M component
IgG 46 80
IgA 7 12
Light chain 2 4
Non-secretory 2 4
K/L 45/11
Salmon and Durie stage
I 14 25
II–III 43 75  
Extramedullary disease 4 7
b2-MG >2.4 mcg/L 21 55*
Creatinine >2 mg/L 4 7
Hb level <8 g/dL 3 5
Bone lesions >1 34 60  
Del13q** 7 50 ***
First line treatment
Conventional 37 65
Autologous stem cell transplantation 14 25
Thalidomide + conventional 6 10
* b2-MG (microglobulin) available in 38 pts. 
**   Assessed by FISH. 
*** Del13q available in 14 pts. 
Table 1
Clinical characte-
ristics of patients 
at diagnosis. COX-2 POS COX-2 NEG p
Age median (range) 64 (36-86) 63 (35-78) 0.97
Sex M/F 19/12 18/8 0.58
Salmon and Durie Stage
Stage I 9/31 (29%) 5/26 (19%) 0.38
Stage II 9/31 (29%) 5/26 (19%) 0.38
Stage III 12/31 (42%) 17/26 (62%) 0.12
b2-MG >2.4 mcg/L 9/16 (56%) 12/22 (54%) 0.95
Creatinine >2 mg/L 2/31 (6%) 2/26 (8%) 0.92
Hb level <8 g/dL 1/31 (3%) 2/26 (8%) 0.52
Bone lesions >1 18/31 (58%) 16/26 (62%) 0.95
Del13q* 4/7 (57%) 3/7 (43%) 1.00
Table 2
COX-2 expression and clinical parameters.
Prognostic factors Hazard ratio 95% CIa p
Age 0.99 0.96–1.03 0.78
Sex 1.53 0.78–3.00 0.22
Stage 0.96 0.64–1.43 0.84
b2-MG 1.33 0.62–2.86 0.47
COX-2 pos 2.01 1.01–4.01 0.046  
a 95% CI, lower and upper limits of the confidence interval  
Table 3
Prognostic factors for time to progression by univariate 
Cox regression.
Figure 1
COX-2 expression in
reactive tissues,
MGUS and multiple
myeloma (MM). 
A Tonsil with strong
positivity in plasma
cells in the sub-en-
dothelial area (aster-
isk) and in germinal
centre (GC). 
B Scattered plasma
cells expressing
COX-2 in an inflamed
appendix. 
C Faint but distinct
positivity in MGUS. 
D Faint expression 
of COX-2 in MM.
E and F: As positive
scored MMs with 
E moderate and 
F strong staining 
intensity. 
Figure 2
Kaplan Meier estimate of probability of TTF in previously
untreated multiple myeloma patients according to COX-2
expression status at diagnosis. Dotted line indicates 
COX-2 positive and solid line COX-2 negative patients by
immunohistochemical expression analysis (p = 0.037).
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However, there was a significant difference for
progression-free survival according to COX-2 
expression on tumours. Patients with COX-2 pos-
itive tumors exhibited a significantly shorter time-
to-progression interval: at diagnosis the median
time to progression was 17 months in COX-2-pos-
itive and 30 months in COX-2-negative patients
(p = 0.037, log-rank test). Figure 2 shows the TTP
curves in our population according to COX-2 sta-
tus. Of note is the finding that when backward
stepwise Cox regression was used for multivariate
analysis of prognostic factors, COX-2 expression
(HR 2.01, 95% CI 1.01–4.01; p = 0.046) remains
the only significant prognostic factor as well.
Among blood-related neoplastic disorders,
MM is an interesting disorder to evaluate for a dis-
turbance of the COX-2 and PG pathways, since
malignant plasma cells are strictly dependent on
microenvironmental factors for survival [3]. Em-
ploying standard IHC, evaluation of sections from
previously untreated MM patients showed that
progression-free survival is significantly impaired
in patients who scored positively for COX-2 im-
munoreactivity as compared to COX-2 negative
tumours (17 months vs 30 months; p = 0.037).
These data are in line with TTP in our previ-
ous molecular study (18 months vs 36 months; 
P <0.001) performed in 122 patients, as well as 
with the results from solid cancers and from one
study investigating a variety of non-Hodgkin lym-
phomas presented so far [2–4]. However, COX-2
was not associated with any of the commonly used
clinicopathological and prognostic indicators eval-
uated, an observation which also remains unclear
in tumours other than MM. Although a correla-
tion between COX-2 and survival analysis in MM
could be established in patients at different phases
of the disease, the present study appeared to be
limited due to the number of events. As could be
expected from its biological role, COX-2 was
found to be expressed in reactive plasmocytosis
and to a slight extent in MGUS, and so does not
necessarily represent a suitable marker to discrim-
inate reactive from pre-malignant or malignant
plasma cell disorders. Future analysis may focus on
identification of MM patients with primary resist-
ance to chemotherapy, possibly induced by the ex-
pression of a multidrug resistance gene in the ma-
lignant clone, and correlation to parameters with
established prognostic relevance in MM [5]. In ad-
dition, the functional status and impact of COX-2
and its modification by different factors such as
NF-kappaB, HIF-1 and cyclin D1, as well as PG-
receptor expression in the tumour microenviron-
ment of MM, is currently being explored [6–8]. 
In summary, we were able to reproduce earlier
mRNA findings on COX-2 expression merely by
IHC on a smaller number of initially untreated
MM patients. Since paraffin immunohistochem-
istry is routinely available, robust and inexpensive,
we suggest that COX-2 IHC in multiple myeloma
should be evaluated in a prospective study for rou-
tine staining using a stringent protocol for fixation
and decalcification steps. Patients with COX-2-
positive multiple myeloma may then benefit from
new targeted inhibitory therapy [9].
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